Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Cell Therapy Catapult & the UK Stem Cell Foundation Agree to Collaborate

Published: Wednesday, April 10, 2013
Last Updated: Wednesday, April 10, 2013
Bookmark and Share
Working together on next-generation medicines for patient benefit.

The Cell Therapy Catapult (CT Catapult), which is focused on the development of the UK cell therapy industry to increase the nation's health and wealth, and the UK Stem Cell Foundation, a charity focused on the advancement of stem cell treatments towards the clinic, are pleased to announce that they will be working together to progress promising stem cell-based therapies in the UK. The two organisations, which have entered into a memorandum of understanding to cover their co-operation, are both focused on translational activities, moving potential therapeutic approaches on from early-stage research to the later stages of development.

The CT Catapult and the charity aim to build a pipeline of projects that meet their criteria for support and funding on the route to commercialisation. Since 2005 the UKSCF has supported projects in a range of indications from spinal cord repair, ophthalmic, liver and cardiac disease, and tendon repair. Building on the UK's early stage research base, the CT Catapult is working on building a similarly broad pipeline. The two organisations will meet regularly to discuss projects and potential support packages, including other partners, contributing to the growth of the UK's emerging cell therapy industry.

Keith Thompson, CEO of the Cell Therapy Catapult, said, 'With the philanthropic sector an increasingly important source of life sciences research funding globally, we are very pleased to be working with the UK Stem Cell Foundation on the development of much needed therapies. The charity is a major UK funder in this area, and exemplifies the kind of high quality organisation the Cell Therapy Catapult expects to collaborate with as it works to build a thriving UK cell therapy industry.'

UKSCF’s CEO Lil Shortland said, 'It is clear that some of the projects we support fit within the remit of the Catapult and would benefit from the specialist support that it can provide. It is vital that there is a joined up approach between public, private and third sector organisations supporting the development of regenerative medicine products in the UK. Each sector has a role to play in realising the potential of stem cells to deliver not just health benefits but economic benefits for the UK and beyond.'


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

UCL, Imperial & Cell Therapy Catapult Collaborate
A novel cell therapy approach to the treatment of acute myeloid leukaemia is to be developed further via the innovative partnership.
Tuesday, May 20, 2014
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!